ArticleAdvanced healthcare materials2025
Evaluation of Engineered Cartilage Composition and Function Using Raman Spectroscopy.
Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multimodal characterization of articular cartilage degeneration in the humeral head using Raman spectroscopy, biomechanics, and imaging.Osteoarthritis and cartilage · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
A Raman spectroscopy-based platform has tremendous potential to non-destructively monitor the evolving composition of tissue-engineered cartilage (TEC) responsible for its mechanical properties from in vitro cultivation to post-implantation in vivo function. Raman spectroscopy, an inelastic light scattering technique, reflects the biochemical building blocks (amides, sulfates, and hydroxyls) comprising a tissue. Here, an arthroscopy-compatible probe acquires Raman spectra, and a multivariate linear decomposition routine extracts the regression coefficient biomarkers that reflect the contribution of extracellular matrix (ECM) constituents (sulfated glycosaminoglycans [sGAG], collagen, water) and the scaffold biomaterial to the tissue spectra. Repeated Raman acquisitions during cultivation do not alter growth of chondrocyte-seeded-agarose constructs. The Raman-derived ECM biomarkers portray the composition of the evolving neocartilage developed on agarose, hyaluronan, collagen, and polyethylene-glycol scaffolds, accounting for 90%, 78%, and 87% of content variation in sGAG, collagen, and water, and 94% of the variation in stiffness. The ECM biomarkers reveal variability in sGAG and collagen content for constructs infused with donor chondrocytes from a 58-year-old/female, a 36-year-old/male, and a 53-year-old/male, accounting for 81% and 87% of the variation in stiffness and sGAG content. This Raman platform offers a transformative approach enabling optimization of construct fabrication, improving preclinical evaluation, and advancing cartilage regenerative therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.